STOCK TITAN

INVITRO INTL - IVRO STOCK NEWS

Welcome to our dedicated page for INVITRO INTL news (Ticker: IVRO), a resource for investors and traders seeking the latest updates and insights on INVITRO INTL stock.

InVitro International is a pioneer in developing test kits for non-animal testing globally, with a focus on providing innovative solutions for industries such as cosmetics, pharmaceuticals, and chemicals. The company offers products like the Irritection Assay System and Corrositex to detect potential irritants and corrosivity. Founded in 1985 and headquartered in Placentia, California, InVitro International also offers technology services for installation and testing processes, along with independent testing laboratory services.

Rhea-AI Summary

InVitro International (OTCQB: IVRO) reported its FY '24 financial results, showing mixed performance. The company achieved sales of $811,290, marking a 2.4% increase compared to FY '23, while net income significantly improved to $106,704 from $1,555 in the previous year. Fourth quarter performance showed sales growth of 19.9% reaching $221,200, although quarterly net income declined 48.8% to $25,122 compared to $49,035 in the same period last year. The company marked its 20th consecutive year of profits and expressed optimism about its M&A growth strategy and non-animal testing business prospects for FY '25.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
none
-
Rhea-AI Summary

InVitro International (OTCQB: IVRO) has announced the engagement of Askew Kabala and Company, Inc. (AKC) as a consultant to support and advance the company's corporate growth plan. AKC will provide business advising, investment banking, management, and strategy services to IVRO. The consulting firm will offer executive and organizational support, including strategy refinement, planning, and operational review.

IVRO CEO W. Richard Ulmer expressed enthusiasm about the partnership, stating that the company is adapting well to post-Covid-19 and inflationary times by adding guidance from experienced professionals. The engagement with AKC comes in the final month of IVRO's Fiscal 2024 Year, signaling a strategic move to enhance the company's growth trajectory.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.89%
Tags
none
-
Rhea-AI Summary

InVitro International (OTCQB: IVRO) reported its Q3 FY '24 financial results, showing a 16% decrease in sales to $167,850 compared to the same quarter last year. However, the company achieved a net income of $16,236, a significant improvement from the $13,162 loss in Q3 FY'23. For the first three quarters of FY'24, sales totaled $590,090, down 3% from FY'23, but year-to-date earnings surged to $81,582, a 272% increase from the prior year's losses. CEO W. Richard Ulmer highlighted the company's focus on maintaining profitability for the 19th consecutive year and pursuing growth through M&A financing and qualifying private laboratories. Ulmer also emphasized the promising future of non-animal testing in the industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

InVitro International reported positive second quarter FY '24 results with sales of $210,615, up 5.8% from the same period in FY '23, and net income of $47,674. First half FY '24 sales increased 3.4% to $422,240, with a net income of $65,342 compared to losses in FY '23. The company is planning an uplisting to OTCQB to enhance visibility and credibility with potential M&A targets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.05%
Tags
-
Rhea-AI Summary
InVitro International (IVRO) reports a 1.1% increase in sales and a 157% rise in profits for the first Quarter FY '24 ending December 31, 2023. CEO W. Richard Ulmer aims for organic growth and M&A activities amidst economic challenges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
InVitro International (IVRO) Announces FY '23 Sales of $792,629 with 7% Decrease from FY '22
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
InVitro International (IVRO) reported a 16% decrease in third quarter sales for Fiscal 2023, totaling $199,855, but achieved a 58% improvement in net loss at $13,162 compared to the prior year. Year-to-date sales for FY '23 are down 10.8% at $608,195, with a net loss of $47,482, including merger-related costs. CEO W. Richard Ulmer highlighted the challenging economic conditions but expressed optimism due to smooth merger progress and potential legislative developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.5%
Tags
-
Rhea-AI Summary

InVitro International (OTC PINK:IVRO) announced its pursuit of strategic partnerships through ongoing Letter of Intent discussions. While outcomes remain uncertain, this move aligns with the company’s goal to advance non-animal testing. Following a robust 3rd Quarter of FY 2021, sales surged by 51% compared to the 2nd Quarter, accompanied by a cash reserve increase to $1.3 million. The company specializes in non-animal testing methods, offering technologies with global reach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.29%
Tags
none
Rhea-AI Summary

InVitro International (OTC PINK:IVRO) reported Q3 FY 2021 revenues of $310,700, a 35% increase year-over-year, and net income of $87,644. Year-to-date net income is $97.7K, up 17% from last year. Cash reserves stand at approximately $1.3M, bolstered by PPP loans. The company aims to enhance its mission of promoting non-animal testing methods, aligning with growing public sentiment against animal testing, amid recent legislative changes in multiple U.S. states.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of INVITRO INTL (IVRO)?

The current stock price of INVITRO INTL (IVRO) is $0.10145 as of December 17, 2024.

What is the market cap of INVITRO INTL (IVRO)?

The market cap of INVITRO INTL (IVRO) is approximately 1.8M.

What does InVitro International specialize in?

InVitro International specializes in developing test kits for non-animal testing in industries like cosmetics, pharmaceuticals, and chemicals.

When was InVitro International founded?

InVitro International was founded in 1985.

Where is InVitro International headquartered?

InVitro International is headquartered in Placentia, California.

What products does InVitro International offer?

InVitro International offers products like the Irritection Assay System and Corrositex to detect potential irritants and corrosivity.

What services does InVitro International provide?

InVitro International provides technology services for installation and testing processes, along with independent testing laboratory services.

Which industries primarily use InVitro International's products?

The products of InVitro International are mainly used by the manufacturers of surfactants, petrochemicals, cosmetics, textiles, pharmaceuticals, and other chemical raw materials.

What is the mission of InVitro International?

The mission of InVitro International is to provide effective non-animal testing methods for various industries by offering innovative solutions and services.

How does InVitro International contribute to animal welfare?

InVitro International contributes to animal welfare by promoting non-animal testing methods that are effective and reliable for industries like cosmetics, pharmaceuticals, and chemicals.

What sets InVitro International apart from its competitors?

InVitro International stands out from its competitors by offering advanced test kits and services for non-animal testing, backed by years of industry experience and expertise.

What are the future goals of InVitro International?

The future goals of InVitro International include expanding its market presence, fostering partnerships, and continuing to innovate in the field of non-animal testing methods.

INVITRO INTL

OTC:IVRO

IVRO Rankings

IVRO Stock Data

1.84M
22.76M
Diagnostics & Research
Healthcare
Link
United States of America
Placentia